FDA Approves Pombiliti Plus Opfolda for Late-Onset Pompe Disease
The unique, 2-component therapy improved walking ability and breathing function in the pivotal phase 3 clinical trial.
United States North Carolina Duke University Priyas Kishnani Drug Administration Genomics Center At Duke University Medical
Source: everydayhealth.com